Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-21
    E.g., 2018-06-21

Archive Search


257247 items
2:10 PM, Jun 21, 2018  |  BC Innovations | Translation in Brief

Liver’s killer instinct

A study in Science suggests natural killer T cells residing in the liver uniquely position the organ to reap antitumor effects from antibiotic-mediated microbiome depletion, uncovering a novel link in the microbiome-cancer relationship that highlights...
2:06 PM, Jun 21, 2018  |  BC Extra | Politics & Policy

Beacon to develop right-to-try patient match platform

Beacon Pharmaceutical (New York, N.Y.) said it will launch a new platform to connect terminally ill patients with experimental therapies under the new right-to-try law. The firm is developing the platform as a philanthropic effort through...
2:05 PM, Jun 21, 2018  |  BC Extra | Company News

UCSD launches bacteriophage treatment center

The University of California San Diego launched the Center for Innovative Phage Applications and Therapeutics (IPATH) to develop bacteriophages to fight multidrug-resistant bacteria. The initial focus will be on treating chronic infections associated with cystic...
1:52 PM, Jun 21, 2018  |  BC Extra | Clinical News

Novo expands market cap on oral semaglutide data

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) added DKK20.4 billion ($3.2 billion) in market cap in Copenhagen on Thursday after reporting that oral diabetes candidate semaglutide was at least non-inferior to two approved therapies in reducing...
1:40 PM, Jun 21, 2018  |  BC Extra | Politics & Policy

FDA releases draft guidance for antidepressant trials

FDA published draft guidance on developing drugs for major depressive disorder, which when finalized will replace the agency's guidance on the topic issued in 1977. Double-blind, placebo-controlled trial designs are the current standard for short-term treatments...
11:57 AM, Jun 21, 2018  |  BC Extra | Clinical News

Heron flying on Phase IIb pain data ahead of NDA

Heron Therapeutics Inc. (NASDAQ:HRTX) added $9.25 (30%) to $39.95 on Thursday after reporting that HTX-011 met the primary endpoint in a pair of Phase IIb trials to treat postoperative pain. The stock move added more...
11:29 AM, Jun 21, 2018  |  BC Innovations | Emerging Company Profile

Getting past PTSD

Neurovation Labs Inc. is developing a GRIA1-targeting tracer and a small molecule therapy that could provide an objective diagnosis of PTSD and treat the underlying disease instead of its just its symptoms. Post-traumatic stress disorder (PTSD)...
10:48 AM, Jun 21, 2018  |  BC Extra | Politics & Policy

FDA scraps biosimilars draft guidance

In an effort to reduce the cost and increase the efficiency of biosimilars development, FDA Thursday withdrew draft guidance on statistical approaches for evaluating analytical similarities between a proposed biosimilar and its reference product. The...
9:49 AM, Jun 21, 2018  |  BC Innovations | Translation in Brief

PHIP the script

Cancers lacking key molecular signatures targeted by precision therapies are among the most challenging to treat, but a new study has identified a target, PHIP, for three of those difficult tumor types. A group led...
7:14 AM, Jun 21, 2018  |  BC Extra | Financial News

Rhythm raises $151.4M in follow-on

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) raised $151.4 million through the sale of 5.7 million shares at $26.42 in a follow-on underwritten by Morgan Stanley, BofA Merrill Lynch, Cowen and Needham. The price is an 8% discount...